表紙:ヒトマイクロバイオーム治療薬市場レポート (2021年~2031年) :技術・治療領域・タイプ・製品・地域&主要国市場の分析、主要企業およびCOVID-19回復シナリオ
市場調査レポート
商品コード
996043

ヒトマイクロバイオーム治療薬市場レポート (2021年~2031年) :技術・治療領域・タイプ・製品・地域&主要国市場の分析、主要企業およびCOVID-19回復シナリオ

Human Microbiome Therapeutics Market Report 2021-2031: Forecasts by Technology, by Therapeutic Area, by Type, by Product, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 492 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=155.67円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ヒトマイクロバイオーム治療薬市場レポート (2021年~2031年) :技術・治療領域・タイプ・製品・地域&主要国市場の分析、主要企業およびCOVID-19回復シナリオ
出版日: 2021年01月04日
発行: Visiongain Ltd
ページ情報: 英文 492 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のヒトマイクロバイオーム治療薬市場について調査し、収益予測に加え、近年の実績・成長率・市場シェア、定性分析 (市場力学、成長要因、機会、抑制要因、課題を含む)、Covid19による影響の分析、および主要企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

  • 要点

第3章 ヒトマイクロバイオーム治療製品と技術の概要

  • ヒトマイクロバイオーム治療製品のイントロダクション
    • ヒトマイクロバイオーム
    • 腸内細菌叢
    • 口腔微生物叢
    • 皮膚マイクロバイオーム
  • マイクロバイオームと人間の健康と病気
  • ヒトマイクロバイオームの本質的な機能
  • 微生物叢調査を支援する技術
  • 栽培と栽培
    • 動物モデル
    • ノトバイオティック動物モデル
    • エンジニアリングシステム
    • オルガノイド培養
    • バイオリアクター
    • 微生物叢アッセイ
    • 直接観察
    • データ解析
  • マイクロバイオーム治療疾患領域
  • マイクロバイオーム治療薬の規制状況
  • 微生物叢調査プロジェクト

第4章 マイクロバイオーム治療薬の開発

  • 添加剤微生物叢療法
  • ライブ生物療法製品(LBP)
  • 調節性微生物叢療法
    • 小分子ポストバイオティクス
    • プレバイオティクス
  • サブトラクティブマイクロバイオーム治療薬
  • 抗菌療法
  • ファージセラピー

第5章 市場力学

  • 概要
  • SWOT分析
  • マイクロバイオーム治療薬市場の推進力
    • 高いアンメットメディカルニーズ
    • マイクロバイオームの理解の高まり
    • ポジティブな投資環境
    • 強力なパイプライン
    • 規制当局からの承認
  • マイクロバイオーム治療薬市場の課題
    • 規制ガイダンスの欠如
    • 製品の特性評価と製造上の課題
    • 前臨床および臨床調査におけるハードル
    • 熟練労働者の必要性
    • 新興市場
    • より良い診断方法の開発
    • 買収とパートナーシップ
  • マイクロバイオーム治療薬市場への脅威
    • 新しい政府規制
    • 世界の市場での激しい競合
    • COVID-19パンデミック

第6章 世界のヒトマイクロバイオーム治療薬市場

  • 世界の市場概要
  • 世界の市場の見通し(COVID-19影響回復分析):金額ベース
  • 地域別の世界の市場の見通し(COVID-19影響回復分析)
  • 技術別の世界の市場の見通し
    • ヒトマイクロバイオーム治療技術の概要
    • 技術別の世界のヒトマイクロバイオーム治療薬市場(COVID-19以前の分析)
    • 技術別の世界のヒトマイクロバイオーム治療薬市場(COVID-19後の影響回復分析)
  • 治療分野別の世界の市場の見通し(COVID-19影響回復分析)
  • タイプ別の世界の市場の見通し
    • 糞便微生物移植(FMT)
    • ライブ生物療法製品(LBP)
    • モノクローナル微生物
    • 人工細菌
    • 調節性マイクロバイオーム治療薬
    • サブトラクティブマイクロバイオーム治療薬
    • タイプ別の世界の市場の見通し(COVID-19以前の分析)
    • タイプ別の世界の市場の見通し(COVID-19後の影響回復分析)
  • 製品別の世界の市場の見通し(COVID-19影響回復分析)

第7章 北米のヒトマイクロバイオーム治療薬市場

  • 北米市場概要
  • 北米市場の見通し(COVID-19影響回復分析):金額ベース
  • 国別の北米市場の見通し(COVID-19影響回復分析)
  • 米国市場の見通し
    • 米国市場の見通し(COVID-19影響回復分析):金額ベース
  • カナダ市場の見通し
    • 価値別のカナダ市場の見通し(COVID-19影響回復分析)
  • テクノロジー別の北米市場の見通し(COVID-19影響回復分析)
  • 治療分野別の北米市場の見通し(COVID-19影響回復分析)
  • タイプ別の北米市場の見通し(COVID-19影響回復分析)
  • 製品別の北米市場の見通し(COVID-19影響回復分析)

第8章 欧州のヒトマイクロバイオーム治療薬市場

  • 欧州市場概要
  • 欧州市場の見通し(COVID-19影響回復分析):金額ベース
  • 国別の欧州市場の見通し(COVID-19影響回復分析)
  • ロシア市場の見通し
    • ロシア市場の見通し(COVID-19影響回復分析):金額ベース
  • ドイツ市場の見通し
  • 英国市場の見通し
  • フランス市場の見通し
  • イタリア市場の見通し
  • その他欧州市場の見通し
  • 技術別の欧州市場の見通し(COVID-19影響回復分析)
  • 治療分野別の欧州市場の見通し(COVID-19影響回復分析)
  • タイプ別の欧州市場の見通し(COVID-19影響回復分析)
  • 製品別の欧州市場の見通し(COVID-19影響回復分析)

第9章 アジア太平洋地域のヒトマイクロバイオーム治療薬市場

  • アジア太平洋市場概要
  • アジア太平洋市場の見通し(COVID-19影響回復分析):金額ベース
  • 国別のアジア太平洋市場の見通し(COVID-19影響回復分析)
  • 日本市場の見通し
    • 日本市場見通し(COVID-19影響回復分析):金額ベース
  • 中国市場の見通し
  • インド市場の見通し
  • 韓国市場の見通し
  • オーストラリア市場の見通し
  • アジア太平洋のその他諸国市場の残りの見通し
  • 技術別のアジア太平洋市場の見通し(COVID-19影響回復分析)
  • 治療分野別のアジア太平洋市場の見通し(COVID-19影響回復分析)
  • タイプ別アジア太平洋市場の見通し(COVID-19影響回復分析)
  • 製品別のアジア太平洋市場の見通し(COVID-19影響回復分析)

第10章 LAMEAヒトマイクロバイオーム治療薬市場

  • LAMEA市場概要
  • LAMEA市場の見通し(COVID-19影響回復分析):金額ベース
  • 国別のLAMEA市場の見通し(COVID-19影響回復分析)
  • ブラジル市場の見通し
    • ブラジル市場の見通し(COVID-19影響回復分析):金額ベース
  • サウジアラビア市場の見通し
  • 南アフリカ市場の見通し
  • メキシコ市場の見通し
  • UAE市場の見通し
  • LAMEA市場の見通しの残り
  • 技術別のLAMEA市場の見通し(COVID-19影響回復分析)
  • 治療分野別のLAMEA市場の見通し(COVID-19影響回復分析)
  • タイプ別LAMEA市場の見通し(COVID-19影響回復分析)
  • 製品別のLAMEA市場の見通し(COVID-19影響回復分析)

第11章 競合情勢分析

  • マイクロバイオーム治療への投資
  • 公的資金調達イニシアチブ
  • 民間資金調達イニシアチブ
    • セブンチャーパートナー
    • フラッグシップパイオニア
  • 世界の市場でのコラボレーションとパートナーシップ
  • ライセンシングおよび製造契約
  • 世界の市場でのM&A
  • マイクロバイオーム治療薬市場の主要な市場プレーヤー
  • 相加マイクロバイオーム治療薬市場の主要な市場プレーヤー
  • 調整マイクロバイオーム治療薬市場の主要な市場プレーヤー
  • 減法マイクロバイオーム治療薬市場の主要な市場プレーヤー

第12章 世界のヒトマイクロバイオーム特許分析

  • 特許の概要
  • 特許分析
  • 年別の特許
  • タイプ別の特許
  • 疾患タイプ別の特許
  • 企業別特許
  • 国別特許
  • 譲受人別特許

第13章 世界のヒトマイクロバイオーム臨床試験分析

  • 疾患カテゴリー別の臨床試験分析
  • 臨床試験のシェア
  • 治療戦略別臨床試験分析
  • 臨床試験のシェア
  • 企業別臨床試験分析
  • 臨床試験のシェア
  • 発見と前臨床開発におけるマイクロバイオーム治療薬
  • フェーズ3のマイクロバイオーム治療薬の臨床試験

第14章 主要企業プロファイル

  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Dow Inc. Chemical
  • Takeda Pharmaceuticals Company Ltd.
  • Johnson & Johnson
  • DuPont de Nemours, Inc
  • Merck & Co. Inc
  • Pfizer Inc.
  • Vertex Pharmaceuticals
  • Evelo Biosciences, Inc
  • Kaleido Biosciences Inc
  • Seres Therapeutics Inc
  • PureTech Health PLC
  • Nestle S.A.
  • Mayo Clinic
  • MaaT Pharma SA
  • 4D Pharma Plc
  • Assembly Biosciences, Inc
  • F. Hoffmann-La Roche Ltd
  • Vedanta Biosciences

第15章 結論と推奨事項

第16章 用語集

図表

List of Figures

  • Figure 1.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 3.1 Differences in Human Genome and Microbiome
  • Figure 3.2 Bacterial Distribution, by Body Site
  • Figure 3.3 Essential Functions of Human Microbiome
  • Figure 5.1 SWOT Analysis of Global Human Microbiome Therapeutics Market
  • Figure 6.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.2 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.3 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.4 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.5 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.6 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.7 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.8 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.9 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.10 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.11 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.12 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.13 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.14 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.15 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.16 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.17 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.18 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.19 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.20 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.21 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.22 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.23 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.24 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.25 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.26 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.27 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.28 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.29 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.30 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.1 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.2 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.3 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.4 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.5 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.6 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.7 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.8 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.9 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.10 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.11 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.12 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.13 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.14 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.15 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.16 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.17 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.18 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.19 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.20 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.21 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.22 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.23 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.24 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.25 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.26 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.27 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.28 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.29 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.30 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.1 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.2 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.3 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.4 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.5 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.6 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.7 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.8 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.9 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.10 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.11 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.12 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.13 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.14 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.15 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.16 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.17 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.18 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.19 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.20 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.21 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.22 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.23 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.24 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.25 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.26 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.27 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.28 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.29 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.30 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.1 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.2 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.3 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.4 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.5 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.6 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.7 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.8 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.9 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.10 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.11 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.12 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.13 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.14 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.15 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.16 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.17 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.18 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.19 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.20 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.21 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.22 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.23 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.24 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.25 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.26 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.27 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.28 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.29 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.30 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.1 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.2 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.3 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.4 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.5 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.6 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.7 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.8 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.9 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.10 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.11 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.12 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.13 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.14 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.15 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.16 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.17 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.18 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.19 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.20 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.21 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.22 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.23 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.24 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.25 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.26 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.27 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.28 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.29 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.30 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 14.1 AbbVie Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.2 AbbVie Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.3 AbbVie Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.4 AbbVie Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.5 Bristol-Myers Squibb: Company Revenue 2015-2019 (US $Mn, AGR %)
  • Figure 14.6 Bristol-Myers Squibb: Company Operating Income 2015-2019 (US $Mn)
  • Figure 14.7 Bristol-Myers Squibb: Company EBITDA 2015-2019 (US $Mn)
  • Figure 14.8 Bristol-Myers Squibb: Company Net Income/Loss 2015-2019 (US $Mn)
  • Figure 14.9 Dow Inc Chemical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.10 Dow Inc Chemical: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.11 Dow Inc Chemical: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.12 Dow Inc Chemical: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.13 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.14 Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.15 Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.16 Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.17 Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.18 Johnson & Johnson: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.19 Johnson & Johnson: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.20 Johnson & Johnson: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.21 KKK: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.22 KKK: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.23 KKK: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.24 KKK: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.25 Merck & Co. Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.26 Merck & Co. Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.27 Merck & Co. Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.28 Merck & Co. Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.29 Pfizer Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.30 Pfizer Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.31 Pfizer Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.32 Pfizer Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.33 Vertex Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.34 Vertex Pharmaceuticals: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.35 Vertex Pharmaceuticals: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.36 Vertex Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.37 Evelo Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.38 Evelo Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.39 Evelo Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.40 Evelo Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.41 Kaleido Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.42 Kaleido Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.43 Kaleido Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.44 Kaleido Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.45 Seres Therapeutics, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.46 Seres Therapeutics, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.47 Seres Therapeutics, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.48 Seres Therapeutics, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.49 PureTech Health Plc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.50 PureTech Health Plc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.51 PureTech Health Plc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.52 PureTech Health Plc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.53 Nestle S.A.: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.54 Nestle S.A.: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.55 Nestle S.A.: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.56 Nestle S.A.: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.57 4D Pharma Plc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.58 4D Pharma Plc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.59 4D Pharma Plc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.60 4D Pharma Plc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.61 Assembly Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.62 Assembly Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.63 Assembly Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.64 Assembly Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.65 F. Hoffmann-La Roche Ltd: Company Revenue 2015-2019 (US $Mn, AGR %)
  • Figure 14.66 F. Hoffmann-La Roche Ltd: Company Operating Income 2015-2019 (US $Mn)
  • Figure 14.67 F. Hoffmann-La Roche Ltd: Company EBITDA 2015-2019 (US $Mn)
  • Figure 14.68 F. Hoffmann-La Roche Ltd: Company Net Income/Loss 2015-2019 (US $Mn)

List of Tables

  • Table 1.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 2.1 Global Human Microbiome Therapeutics Market Summary Table
  • Table 3.1 Technologies for Microbiome Research
  • Table 3.2 Dysbiosis in Microbiome
  • Table 6.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.2 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.3 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.4 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.5 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.6 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.7 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.8 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.9 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.10 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.11 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.12 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.13 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.14 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.15 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.16 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.17 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.18 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.19 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.20 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.21 Modulatory Microbiome Therapeutics
  • Table 6.22 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.23 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.24 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.25 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.26 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.27 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.28 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.29 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.30 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.31 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.1 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.2 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.3 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.4 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.5 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.6 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.7 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.8 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.9 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.10 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.11 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.12 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.13 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.14 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.15 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.16 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.17 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.18 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.19 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.20 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.21 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.22 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.23 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.24 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.25 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.26 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.27 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.28 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.29 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.30 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.31 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.32 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.33 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.34 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.35 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.1 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.2 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.3 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.4 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.5 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.6 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.7 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.8 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.9 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.10 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.11 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.12 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.13 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.14 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.15 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.16 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.17 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.18 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.19 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.20 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.21 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.22 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.23 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.24 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.25 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.26 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.27 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.28 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.29 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.30 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.31 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.32 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.33 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.34 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.35 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.36 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.37 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.38 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.39 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.40 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.41 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.42 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.43 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.44 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.45 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.46 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.47 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.48 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.49 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.50 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.51 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.52 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.53 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.54 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.55 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.1 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.2 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.3 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.4 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.5 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.6 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.7 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.8 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.9 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.10 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.11 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.12 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.13 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.14 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.15 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.16 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.17 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.18 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.19 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.20 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.21 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.22 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.23 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.24 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.25 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.26 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.27 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.28 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.29 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.30 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.31 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.32 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.33 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.34 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.35 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.36 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.37 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.38 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.39 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.40 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.41 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.42 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.43 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.44 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.45 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.46 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.47 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.48 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.49 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.50 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.51 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.52 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.53 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.54 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.55 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.1 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.2 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.3 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.4 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.5 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.6 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.7 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.8 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.9 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.10 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.11 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.12 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.13 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.14 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.15 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.16 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.17 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.18 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.19 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.20 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.21 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.22 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.23 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.24 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.25 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.26 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.27 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.28 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.29 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.30 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.31 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.32 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.33 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.34 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.35 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.36 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.37 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.38 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.39 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.40 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.41 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.42 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.43 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.44 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.45 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.46 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.47 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.48 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.49 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.50 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.51 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.52 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.53 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.54 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.55 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 11.1 Historical Funding Activity in Microbiome Therapeutics, 2015 and 2016
  • Table 11.2 Public Funding in Microbiome Therapeutics, 2018-August 2020
  • Table 11.3 Venture Funding in Microbiome Therapeutics, 2017-August 2020
  • Table 11.4 Collaborations and Partnerships in the Microbiome Therapeutics Market, 2017-August 2020
  • Table 11.5 Licensing and Manufacturing Agreements in the Microbiome Therapeutics Market, 2017-August 2020
  • Table 11.6 Leading Developers of Additive Microbiome Therapeutics, 2019
  • Table 11.7 Leading Developers of Modulatory Microbiome Therapeutics, 2019
  • Table 11.8 Leading Developers of Subtractive Microbiome Therapeutics, 2019
  • Table 12.1 Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020 (Number)
  • Table 12.2 Patents Issued for Microbiome Therapeutics, by Type, 2017- August 2020 (Number/%)
  • Table 12.3 Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020 (Number/%)
  • Table 12.4 Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020 (Number)
  • Table 12.5 Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020 (Number/%)
  • Table 12.6 Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020 (Number/%)
  • Table 13.1 Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020 (Number)
  • Table 13.2 Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020 (%)
  • Table 13.3 Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
  • Table 13.4 Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy (%)
  • Table 13.5 Clinical Trials in Microbiome Therapeutics, by Company
  • Table 13.6 Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies (%)
  • Table 13.7 Microbiome Therapeutics in Discovery and Preclinical Development
  • Table 13.8 Microbiome Therapeutics Clinical Trials in Phase 3
  • Table 14.1 AbbVie Inc: Company Information
  • Table 14.2 AbbVie Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 14.3 AbbVie Inc: Company Product and Service Offerings
  • Table 14.4 AbbVie Inc: Company Product Pipeline
  • Table 14.5 AbbVie Inc: Company Recent Developments till Sept,2020
  • Table 14.6 Bristol-Myers Squibb: Company Information
  • Table 14.7 Bristol-Myers Squibb: Company Revenue 2015-2019 (US $Mn, AGR %)
  • Table 14.8 Bristol-Myers Squibb: Company Product and Service Offerings
  • Table 14.9 Bristol-Myers Squibb: Company Product Pipeline
  • Table 14.17 Takeda Pharmaceuticals: Company Product and Service Offerings

List of Companies Profiled:

  • 4D pharma plc (4D)
  • AbbVie Inc. (AbbVie)
  • Assembly Biosciences, Inc
  • Bristol-Myers Squibb
  • Dow Inc Chemical
  • DuPont de Nemours, Inc.
  • Evelo Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Kaleido Biosciences, Inc.
  • MaaT Pharma SA
  • Mayo Clinic
  • Merck & Co. Inc
  • Nestle S.A.
  • Pfizer Inc.
  • PureTech Health PLC
  • Seres Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vedanta Biosciences
  • Vertex Pharmaceuticals

List of Other Companies:

  • Accinov
  • ActoGeniX
  • Aju IB Investment
  • Ally Bridge Group
  • Amrita Therapeutics
  • AOBiome, LLC
  • AquaBounty Technologies
  • Arctic Aurora Life Science
  • Assembly Biosciences
  • Azitra
  • BaseClear
  • Bio-Technology General
  • BIOASTER
  • Biological & Popular Culture, Inc.
  • BiomX
  • Bioverativ Therapeutics
  • Blue Turtle Bio
  • Bristol-Myers Squibb
  • BYTC Corp
  • C3J Therapeutics
  • Caelus Health
  • Cd4 Biosciences, Inc.
  • Cedars-Sinai Medical Centre
  • Chengdu Sen Nuo Wei Biotechnology Co., Ltd
  • CLI Ventures
  • Codexis Laboratories Hungary Kft
  • CoreBiome
  • Crestovo
  • CRS Bio, Inc
  • DayTwo
  • Effective Pharmaceuticals, Inc.
  • Enterome Bioscience
  • Enterome SA
  • EnviroFlight, LLC
  • Epibiome
  • Epitope Pharmaceuticals, Inc.
  • Evelo Biosciences
  • Evolve BioSystems
  • Ferring Pharmaceuticals
  • Ferring Sas
  • Finch Therapeutics
  • Finch Therapeutics Group, Inc.
  • Genomatix Ltd.
  • Genten Therapeutics, Inc.
  • GenVec, Inc.
  • Global Bioscience Company
  • GT Biologics Limited
  • Hartlab LLC
  • Harvest Capital Strategies, LLC
  • HealthMine, Inc
  • IBBL
  • iCarbonX
  • Igen Biotech Group
  • ImmuneBiotech AB
  • Immuron, Ltd.
  • INC Research
  • Intrexon Actobiotics N.V.
  • Intrexon Energy Partners II, LLC
  • Janssen Biotech
  • Kallyope
  • Leading Biosciences
  • LNC Therapeutics
  • Lundbeckfond Ventures
  • MaaT Pharma SA
  • MatriSys Bioscience
  • Microbiome Therapeutics, LLC
  • Microbiomics Limited
  • Mirna Therapeutics
  • Nitrocell
  • NIZO
  • Nubiyota
  • NuMe Health LLC
  • Okanagan Specialty Fruits Inc.
  • Omnes Capital
  • OpenBiome
  • OptiBiotix Health plc
  • OrbiMed HealthCare Fund Management
  • Osel, Inc.
  • OvaXon, LLC
  • Oxitec
  • Symbiotix Biotherapies
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Synthetic Genomics, Inc.
  • TargEDys
  • Tech Coast Angels (TCA)
  • The Microbiota Company Limited
  • Trans Ova Genetics LC
  • Tucana Health Limited
  • Vedanta Biosciences Inc.
  • Veristat
  • Vertex Pharmaceuticals Inc.
  • Whole Biome
  • Xycrobe Therapeutics

List of Organizations Mentioned in the Report:

  • Alimentary Pharmabiotic Centre
  • APC Microbiome Institute
  • Central Drugs Standard Control Organisation (CDSCO)
  • French National Institute for Agricultural Research
  • Hadasit Medical Research Services & Development Ltd
  • Hadassah Medical Center
  • Health Canada
  • Institut National de la Recherche Agronomique
  • John Theurer Cancer Center of Hackensack Meridian Health
  • King's College London
  • La Trobe University
  • Lawrence Berkeley National Laboratory
  • Leiden University Medical Center
  • Mayo clinic
  • Medical University of Graz
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Medicines Control Council (MCC)
  • Memorial Sloan Kettering Cancer Center
  • Microbiome Institute at University College Cork
  • Ministry of Health, Labour and Welfare (MHLW)
  • Monash University
  • Murdoch Children Research Institute
  • National Institute of Allergy and Infectious Diseases
  • NYU Langone Health
  • Orange Country Research Center
  • Pan American Health Organization (PAHO)
  • Roswell Park Comprehensive Cancer Center
  • Ruprecht-Karls-University Heidelberg
  • Saudi Food and Drug Authority (SFDA)
  • St. Joseph's Hamilton
  • Stanford Cancer Institute
  • The Endocrine Society
  • The Parker Institute for Cancer Immunotherapy
  • Therapeutic Goods Administration (TGA)
  • University of British Columbia
  • University of California
  • University of Melbourne
  • University of Minnesota
  • University of Nebraska
  • University of Pennsylvania
  • University of South Alabama (USA) Mitchell Cancer Institut
  • University of Texas at Austin
  • University of Texas MD Anderson Cancer Center
  • University of Tokyo
  • USA Mitchell Cancer Center
  • World Health Organization (WHO)
  • World Intellectual Property Organization WIPO
  • World Trade Organization (WTO)
目次
Product Code: PHA1025

Title:
Human Microbiome Therapeutics Market Report 2021-2031
Forecasts by Technology (Genomics, Proteomics, Metabolomics), by Therapeutic Area (Neurological Disorders, Dermatological Indications, Cancers, Metabolic Disorders, Gastrointestinal Disorders, Other Therapeutic Areas), by Type (Faecal Microbiota Transplantation (FMT), Microbiome Drugs, Microbiome Rebuilding, Microbiome Preserving), by Product (Probiotics & Prebiotics, Medical Food, Diagnostic Tests, Other Product) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Human Microbiome Therapeutics Companies AND COVID-19 Recovery Scenarios.

What is holding you back in the Human Microbiome Therapeutics Business?

Microbiome therapeutics have emerged as a novel therapeutic strategy, whereby living microbial cells or their components and metabolites are exploited to treat various diseases. Faecal microbial transplants (FMTs) have proved their success in treating recurring Clostridium difficile infections (CDI) for a long time. The potential of microbial therapeutics to address unmet medical needs has, therefore, been attracting many small- and big-players in this area. Still many human microbiome therapeutics companies are unable to make a move and grab this opportunity. In this report we have closely analysed human microbiome therapeutics market to find out a successful way out to grow in this tough crisis too. Buy our report to explore the goldmine areas in the global human microbiome therapeutics market.

Our 490+ page report provides 377 tables, 375 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing human microbiome therapeutics market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter's Five Forces Analysis, product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Discover sales predictions for the global human microbiome therapeutics market and submarkets

Along with revenue prediction for the overall world market, there are 5 segmentations of the human microbiome therapeutics market, with forecasts for 3 technologies, 6 Therapeutic Area, 3 Types, 4 Products each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth

As per Visiongain analysis, global human microbiome therapeutics market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

What all Segments Are Covered in the Report?

Global Human Microbiome Therapeutics Market by Technology (COVID-19 Impact Recovery Analysis Covered)

  • Genomics
  • Proteomics
  • Metabolomics

Global Human Microbiome Therapeutics Market by Therapeutic Area (COVID-19 Impact Recovery Analysis Covered)

  • Neurological Disorders
  • Dermatological Indications
  • Cancers
  • Metabolic Disorders
  • Gastrointenstinal Disorders
  • Other Therapeutic Areas

Global Human Microbiome Therapeutics Market by Type (COVID-19 Impact Recovery Analysis Covered)

  • Fecal Microbiota Transplantation (FMT)
  • Microbiome Drugs
  • Microbiome Rebuilding
  • Microbiome Preserving

Global Human Microbiome Therapeutics Market by Product (COVID-19 Impact Recovery Analysis Covered)

  • Probiotics & Prebiotics
  • Medical Food
  • Diagnostic Tests
  • Other Product

Global Human Microbiome Therapeutics Market by Region (COVID-19 Impact Recovery Analysis Covered)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa

Which Key Players Are Leading the Global Market and how much share do they Hold?

The global market for human microbiome therapeutics is ascending and has made significant gains in therapeutic treatments. The players in the human microbiome therapeutics market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:

  • Mergers and acquisitions.
  • Product launches.
  • Collaborations and partnerships.

Product approval is a major milestone facing all key competitors in the human microbiome therapeutics market. Several strategies were implemented by key market players between 2015 and Dec 2020. There are over 200 microbiome companies involved in different aspects of microbiome therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Human Microbiome Therapeutics Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated

  • What is the current size of the overall global human human microbiome therapeutics market? How much will this market be worth from 2021 to 2031?
  • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are some of the most prominent human human microbiome therapeutics currently in development?
  • What are the main trends that will affect the world human microbiome therapeutics market between 2021 and 2031?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that industry over the next ten years?
  • How will the global human microbiome therapeutics market evolve over the forecasted period, 2021 to 2031?
  • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2021 to 2031?
  • Which therapies can succeed and what revenues could they generate to 2031?
  • What will be the main commercial drivers for the market from 2021 to 2031?
  • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2021 and 2031, especially in R&D?

Top 20 Leading Players Profiled in the Report:

  • AbbVie Inc. (AbbVie)
  • Bristol-Myers Squibb
  • Dow Inc Chemical
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • DuPont de Nemours, Inc.
  • Merck & Co. Inc
  • Pfizer Inc.
  • Vertex Pharmaceuticals
  • Evelo Biosciences, Inc.
  • Kaleido Biosciences, Inc.
  • Seres Therapeutics, Inc.
  • PureTech Health PLC
  • Nestle S.A.
  • Mayo Clinic
  • MaaT Pharma SA
  • 4D pharma plc (4D)
  • Assembly Biosciences, Inc
  • F. Hoffmann-La Roche Ltd
  • Vedanta Biosciences

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the precision cancer diagnostic tests Market and leading companies. You will find data, trends and predictions.

Buy our report today " Human Microbiome Therapeutics Market Report 2021-2031: Forecasts by Technology (Genomics, Proteomics, Metabolomics), by Therapeutic Area (Neurological Disorders, Dermatological Indications, Cancers, Metabolic Disorders, Gastrointestinal Disorders, Other Therapeutic Areas), by Type (Faecal Microbiota Transplantation (FMT), Microbiome Drugs, Microbiome Rebuilding, Microbiome Preserving), by Product (Probiotics & Prebiotics, Medical Food, Diagnostic Tests, Other Product) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Human Microbiome Therapeutics Companies AND COVID-19 Recovery Scenarios". Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1 Report Overview

  • 1.1 Global Human Microbiome Therapeutics Market Overview
  • 1.2 Study Goals and Objectives
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.1 Key Questions Answered by This Analytical Report Include:
  • 1.2 Who is This Report For?
  • 1.3 Methodology
    • 1.4.1 Primary Research
    • 1.4.2 Secondary Research
    • 1.4.3 Data Sources
  • 1.4 Market Evaluation & Forecasting Methodology
  • 1.5 COIVD-19 Impact Recovery Pattern Analysis
    • 1.4.4 V-Shaped Recovery
    • 1.4.5 U-Shaped Recovery
    • 1.4.6 W-Shaped Recovery
    • 1.4.7 L-Shaped Recovery
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2 Executive Summary

  • 2.1 Key Take Away

3 Human Microbiome Therapeutics Products and Technology Overview

  • 3.1 Introduction to Human Microbiome Therapeutics Products
    • 3.1.1 The Human Microbiome
    • 3.1.2 Gut Microbiome
    • 3.1.3 Oral Microbiome
    • 3.1.4 Skin Microbiome
  • 3.2 Microbiome and Human Health and Disease
  • 3.3 Essential Functions of Human Microbiome
  • 3.4 Technologies Aiding Microbiome Research
  • 3.5 Culturing and Cultivation
    • 3.5.1 Animal Models
    • 3.5.2 Gnotobiotic Animal Models
    • 3.5.3 Engineered Systems
    • 3.5.4 Organoid Cultures
    • 3.5.5 Bioreactors
    • 3.5.6 Microbiome Assaying
    • 3.5.7 Direct Observation
    • 3.5.8 Data Analysis
  • 3.6 Microbiome Therapeutics Disease Areas
  • 3.7 Regulatory Landscape for Microbiome Therapeutics
  • 3.8 Microbiome Research Projects

4 Development of Microbiome Therapeutics

  • 4.1 Additive Microbiome Therapy
  • 4.2 Live Biotherapeutic Products (LBPs)
  • 4.3 Modulatory Microbiome Therapy
    • 4.3.1 Small Molecule Postbiotics
    • 4.3.2 Prebiotics
  • 4.4 Subtractive Microbiome Therapeutics
  • 4.5 Antimicrobial Therapy
  • 4.6 Phage Therapy

5 Market Dynamics

  • 5.1 Overview
  • 5.2 SWOT Analysis
  • 5.3 Drivers of Microbiome Therapeutics Market
    • 5.3.1 High Unmet Medical Need
    • 5.3.2 Growing Understanding of the Microbiome
    • 5.3.3 Positive Investment Environment
    • 5.3.4 Strong Pipeline
    • 5.3.5 Acceptance from Regulatory Authorities
  • 5.4 Challenges for Microbiome Therapeutics Market
    • 5.4.1 Lack of Regulatory Guidance
    • 5.4.2 Product Characterization and Manufacturing Challenges
    • 5.4.3 Hurdles in Preclinical and Clinical Research
    • 5.4.4 Need for Skilled Labor
    • 5.4.5 Emerging Markets
    • 5.4.6 Development of Better Diagnostic Methods
    • 5.4.7 Acquisitions and Partnerships
  • 5.5 Threats to the Microbiome Therapeutics Market
    • 5.5.1 New Government Regulations
    • 5.5.2 Stiff Competition in the Global Market
    • 5.5.3 COVID-19 Pandemic

6 Global Human Microbiome Therapeutics Market

  • 6.1 Global Market Overview
  • 6.2 Global Market Outlook in terms of Value (COVID-19 Impact Recovery Analysis)
  • 6.3 Global Market Outlook by Region (COVID-19 Impact Recovery Analysis)
  • 6.4 Global Market Outlook by Technology
    • 6.4.1 Human Microbiome Therapeutics Technology Overview
    • 6.4.2 Global Human Microbiome Therapeutics Market by Technology (Pre-COVID-19 Analysis)
    • 6.4.3 Global Human Microbiome Therapeutics Market by Technology (Post-COVID-19 Impact Recovery Analysis)
  • 6.5 Global Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 6.6 Global Market Outlook by Type
    • 6.6.1 Fecal Microbiota Transplants (FMTs)
    • 6.6.2 Live Biotherapeutic Products (LBPs)
    • 6.6.3 Monoclonal Microbials
    • 6.6.4 Engineered Bacteria
    • 6.6.5 Modulatory Microbiome Therapeutics
    • 6.6.6 Subtractive Microbiome Therapeutics
    • 6.6.7 Global Market Outlook by Type (Pre-COVID-19 Analysis)
    • 6.6.8 Global Market Outlook by Type (Post-COVID-19 Impact Recovery Analysis)
  • 6.7 Global Market Outlook by Product (COVID-19 Impact Recovery Analysis)

7 North America Human Microbiome Therapeutics Market

  • 7.1 North America Market Overview
  • 7.2 North America Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 7.3 North America Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 7.4 US Market Outlook
    • 7.4.1 US Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 7.5 Canada Market Outlook
    • 7.5.1 Canada Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 7.6 North America Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 7.7 North America Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 7.8 North America Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 7.9 North America Market Outlook by Product (COVID-19 Impact Recovery Analysis)

8 Europe Human Microbiome Therapeutics Market

  • 8.1 Europe Market Overview
  • 8.2 Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.3 Europe Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 8.4 Russia Market Outlook
    • 8.4.1 Russia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.5 Germany Market Outlook
    • 8.5.1 Germany Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.6 UK Market Outlook
    • 8.6.1 UK Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.7 France Market Outlook
    • 8.7.1 France Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.8 Italy Market Outlook
    • 8.8.1 Italy Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.9 Rest of Europe Market Outlook
    • 8.9.1 Rest of Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.10 Europe Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 8.11 Europe Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 8.12 Europe Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 8.13 Europe Market Outlook by Product (COVID-19 Impact Recovery Analysis)

9 Asia-Pacific Human Microbiome Therapeutics Market

  • 9.1 Asia-Pacific Market Overview
  • 9.2 Asia-Pacific Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.3 Asia-Pacific Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 9.4 Japan Market Outlook
    • 9.4.1 Japan Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.5 China Market Outlook
    • 9.5.1 China Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.6 India Market Outlook
    • 9.6.1 India Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.7 South Korea Market Outlook
    • 9.7.1 South Korea Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.8 Australia Market Outlook
    • 9.8.1 Australia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.9 Rest of APAC Market Outlook
    • 9.9.1 Rest of APAC Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.10 Asia-Pacific Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 9.11 Asia-Pacific Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 9.12 Asia-Pacific Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 9.13 Asia-Pacific Market Outlook by Product (COVID-19 Impact Recovery Analysis)

10 LAMEA Human Microbiome Therapeutics Market

  • 10.1 LAMEA Market Overview
  • 10.2 LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.3 LAMEA Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 10.4 Brazil Market Outlook
    • 10.4.1 Brazil Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.5 Saudi Arabia Market Outlook
    • 10.5.1 Saudi Arabia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.6 South Africa Market Outlook
    • 10.6.1 South Africa Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.7 Mexico Market Outlook
    • 10.7.1 Mexico Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.8 UAE Market Outlook
    • 10.8.1 UAE Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.9 Rest od LAMEA Market Outlook
    • 10.9.1 Rest of LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.10 LAMEA Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 10.11 LAMEA Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 10.12 LAMEA Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 10.13 LAMEA Market Outlook by Product (COVID-19 Impact Recovery Analysis)

11 Competitive Landscape Analysis

  • 11.1 Investment in Microbiome Therapeutics
  • 11.2 Public Funding Initiatives
  • 11.3 Private Funding Initiatives
    • 11.3.1 Seventure Partners
    • 11.3.2 Flagship Pioneering
  • 11.4 Collaborations and Partnerships in the Global Market
  • 11.5 Licensing and Manufacturing Agreements
  • 11.6 Mergers and Acquisitions in the Global Market
  • 11.7 Leading Market Players in Microbiome Therapeutics Market
  • 11.8 Leading Market Players in Additive Microbiome Therapeutics Market
  • 11.9 Leading Market Players in Modulatory Microbiome Therapeutics Market
  • 11.10 Leading Market Players in Subtractive Microbiome Therapeutics Market

12 Global Human Microbiome Patent Analysis

  • 12.1 Patent Overview
  • 12.2 Patent Analysis
  • 12.3 Patents by Year
  • 12.4 Patents by Type
  • 12.5 Patents by Disease Type
  • 12.6 Patents by Company
  • 12.7 Patents by Country
  • 12.8 Patents by Assignee

13 Global Human Microbiome Clinical Trial Analysis

  • 13.1 Clinical Trial Analysis by Disease Category
  • 13.2 Share of Clinical Trials
  • 13.3 Clinical Trial Analysis by Treatment Strategy
  • 13.4 Share of Clinical Trials
  • 13.5 Clinical Trial Analysis by Company
  • 13.6 Share of Clinical Trials
  • 13.7 Microbiome Therapeutics in Discovery and Preclinical Development
  • 13.8 Microbiome Therapeutics Clinical Trials in Phase 3

14 Leading Company Profiles

  • 14.1 AbbVie Inc. Company
    • 14.1.1 Company Information
    • 14.1.2 Company Overview
    • 14.1.3 Company Financial Profile
    • 14.1.4 Company Product Offerings
    • 14.1.5 Company Recent Developments
  • 14.2 Bristol-Myers Squibb Company
    • 14.2.1 Company Information
    • 14.2.2 Company Overview
    • 14.2.3 Company Financial Profile
    • 14.2.4 Company Product Offerings
    • 14.2.5 Company Recent Developments
  • 14.3 Dow Inc. Chemical Company
    • 14.3.1 Company Information
    • 14.3.2 Company Overview
    • 14.3.3 Company Financial Profile
    • 14.3.4 Company Product Offerings
    • 14.3.5 Company Recent Developments
  • 14.4 Takeda Pharmaceuticals Company Ltd.
    • 14.4.1 Company Information
    • 14.4.2 Company Overview
    • 14.4.3 Company Financial Profile
    • 14.4.4 Company Product Offerings
    • 14.4.5 Company Recent Developments
  • 14.5 Johnson & Johnson Company
    • 14.5.1 Company Information
    • 14.5.2 Company Overview
    • 14.5.3 Company Financial Profile
    • 14.5.4 Company Product Offerings
    • 14.5.5 Company Recent Developments
  • 14.6 DuPont de Nemours, Inc Company
    • 14.6.1 Company Information
    • 14.6.2 Company Overview
    • 14.6.3 Company Financial Profile
    • 14.6.4 Company Product Offerings
    • 14.6.5 Company Recent Developments
  • 14.7 Merck & Co. Inc Company
    • 14.7.1 Company Information
    • 14.7.2 Company Overview
    • 14.7.3 Company Financial Profile
    • 14.7.4 Company Product Offerings
    • 14.7.5 Company Recent Developments
  • 14.8 Pfizer Inc. Company
    • 14.8.1 Company Information
    • 14.8.2 Company Overview
    • 14.8.3 Company Financial Profile
    • 14.8.4 Company Product Offerings
    • 14.8.5 Company Recent Developments
  • 14.9 Vertex Pharmaceuticals Company
    • 14.9.1 Company Information
    • 14.9.2 Company Overview
    • 14.9.3 Company Financial Profile
    • 14.9.4 Company Product Offerings
    • 14.9.5 Company Recent Developments
  • 14.10 Evelo Biosciences, Inc Company
    • 14.10.1 Company Information
    • 14.10.2 Company Overview
    • 14.10.3 Company Financial Profile
    • 14.10.4 Company Product Offerings
    • 14.10.5 Company Recent Developments
  • 14.11 Kaleido Biosciences Inc Company
    • 14.11.1 Company Information
    • 14.11.2 Company Overview
    • 14.11.3 Company Financial Profile
    • 14.11.4 Company Product Offerings
    • 14.11.5 Company Recent Developments
  • 14.12 Seres Therapeutics Inc Company
    • 14.12.1 Company Information
    • 14.12.2 Company Overview
    • 14.12.3 Company Financial Profile
    • 14.12.4 Company Product Offerings
    • 14.12.5 Company Recent Developments
  • 14.13 PureTech Health PLC Company
    • 14.13.1 Company Information
    • 14.13.2 Company Overview
    • 14.13.3 Company Financial Profile
    • 14.13.4 Company Product Offerings
    • 14.13.5 Company Recent Developments
  • 14.14 Nestle S.A. Company
    • 14.14.1 Company Information
    • 14.14.2 Company Overview
    • 14.14.3 Company Financial Profile
    • 14.14.4 Company Product Offerings
    • 14.14.5 Company Recent Developments
  • 14.15 Mayo Clinic Company
    • 14.15.1 Company Information
    • 14.15.2 Company Overview
    • 14.15.3 Company Financial Profile
    • 14.15.4 Company Product Offerings
    • 14.15.5 Company Recent Developments
  • 14.16 MaaT Pharma SA Company
    • 14.16.1 Company Information
    • 14.16.2 Company Overview
    • 14.16.3 Company Financial Profile
    • 14.16.4 Company Product Offerings
    • 14.16.5 Company Recent Developments
  • 14.17 4D Pharma Plc Company
    • 14.17.1 Company Information
    • 14.17.2 Company Overview
    • 14.17.3 Company Financial Profile
    • 14.17.4 Company Product Offerings
    • 14.17.5 Company Recent Developments
  • 14.18 Assembly Biosciences, Inc Company
    • 14.18.1 Company Information
    • 14.18.2 Company Overview
    • 14.18.3 Company Financial Profile
    • 14.18.4 Company Product Offerings
    • 14.18.5 Company Recent Developments
  • 14.19 F. Hoffmann-La Roche Ltd Company
    • 14.19.1 Company Information
    • 14.19.2 Company Overview
    • 14.19.3 Company Financial Profile
    • 14.19.4 Company Product Offerings
    • 14.19.5 Company Recent Developments
  • 14.20 Vedanta Biosciences Company
    • 14.20.1 Company Information
    • 14.20.2 Company Overview
    • 14.20.3 Company Financial Profile
    • 14.20.4 Company Product Offerings
    • 14.20.5 Company Recent Developments

15 Conclusion & Recommendations

16 Glossary